MRUS Dec 2024 55.000 put
- Insider Monkey
TimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS)
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter the fund returned -1.59% (gross) and -1.83% (net), compared to a -2.92% return for the Russell 2000 Growth Index. The equity markets performed well in […]
- GlobeNewswire
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
Petosemtamab in 2L+ HNSCC interim clinical data selected for rapid oral presentationUTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the acceptance of an abstract on petosemtamab, a Biclonics® targeting EGFR and LGR5, in previously treated (2L+) patients with recurre
- Insider Monkey
Merus NV (MRUS): Short Seller Sentiment is Bearish on This Cancer Stock
We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are going to take a look at where Merus NV (NASDAQ:MRUS) stands against the other cancer stocks. Cancer is the second leading cause of death globally, just behind cardiovascular disease, making oncology one of […]
